Corcept Therapeutics (CORT) Capital Expenditures Growth (1y) (2013 - 2026)
Powered by 
Analysis
Corcept Therapeutics (CORT) Capital Expenditures Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Corcept Therapeutics | 11.76 Bn | 11.46 Bn | 252.09 Mn | 4,335.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4,335.09% |
| Mar 31, 2026 | 93.27% |
| Dec 31, 2025 | -58.68% |
| Jun 30, 2025 | -86.30% |
| Sep 30, 2024 | 4,318.92% |
| Jun 30, 2024 | 307.84% |
| Sep 30, 2023 | -89.46% |
| Jun 30, 2023 | 436.84% |
| Dec 31, 2022 | -52.31% |
| Sep 30, 2022 | 120.75% |
| Jun 30, 2022 | -84.03% |
| Mar 31, 2022 | -90.48% |
| Dec 31, 2021 | -84.92% |
| Sep 30, 2021 | -77.86% |
| Jun 30, 2021 | 153.19% |
| Mar 31, 2021 | 200.00% |
| Dec 31, 2020 | 219.26% |
| Sep 30, 2020 | 151.05% |
| Jun 30, 2020 | -88.54% |
| Mar 31, 2020 | -83.66% |